Table 1.
Demographic and clinical features of study participants
| All (n = 121) | Primary AI (n = 40) | Secondary AI (n = 81) | p value | |
|---|---|---|---|---|
| Gender | 0.033 | |||
| Male | 59 (48.8) | 14 (35.0) | 45 (55.6) | |
| Female | 62 (51.2) | 26 (65.0) | 36 (44.4) | |
| Age (years) | 55.3 ± 17.0 (15.0–84.0) | 49.0 ± 15.8 (15.0–83.0) | 58.5 ± 16.8 (18.0–84.0) | 0.002 |
| Weight (kg) | 73.4 ± 17.0 (44.0–140.0) | 68.3 ± 13.2 (49.0–95.0) | 75.9 ± 18.2 (44.0–140.0) | 0.026 |
| BMI (kg/m2) | 26.2 ± 4.5 (18.8–41.8) | 25.5 ± 4.0 (18.8–34.9) | 26.6 ± 4.8 (19.0–41.8) | NS |
| Glucocorticoid replacement | < 0.0001 | |||
| CA | 52 (43.0) | 7 (17.5) | 45 (55.6) | |
| HC | 65 (53.7) | 32 (80.0) | 33 (40.7) | |
| PRED | 3 (2.5) | 0 | 3 (3.7) | |
| DEX | 1 (0.8) | 1 (2.5) | 0 | |
| Glucocorticoid dose (mg HC/day) | 18.7 ± 7.2 (5.0–35.0) | 20.8 ± 7.2 (5.0–35.0) | 17.7 ± 7.0 (5.0–35.0) | 0.030 |
| Lockdown stress dose | NS | |||
| Yes | 14 (11.6) | 6 (15.0%) | 8 (9.9) | |
| No | 107 (88.4) | 34 (85.0%) | 73 (90.1) | |
| Stress dose (mg HC/day) | 20.7 ± 33.9 (2.5–100.0) | 23.3 ± 38.0 (5.0–100.0) | 18.8 ± 33.1 (5.0–100.0) | NS |
| Stress dose duration (weeks) | NS | |||
| < 1 | 6 (42.9) | 4 (66.7) | 2 (25.0) | |
| 1–2 | 2 (14.3) | 0 | 2 (25.0) | |
| 2–3 | 0 | 0 | 0 | |
| 3–4 | 2 (14.3) | 1 (16.7) | 1 (12.5) | |
| > 4 | 2 (14.3) | 1 (16.7) | 1 (12.5) | |
| Not known | 2 (14.3) | 0 | 2 (25.0) | |
| Mineralocorticoid replacement | NA | |||
| Yes | NA | 36 (90) | NA | |
| No | NA | 4 (10) | NA | |
| Comorbidities | ||||
| Diabetes mellitus | 10 (8.3) | 4 (10) | 6 (7.4) | NS |
| Hypertension | 33 (27.3) | 6 (15) | 27 (33.3) | 0.033 |
| Overweight/obesity | 65 (53.7) | 19 (47.5) | 46 (56.8) | NS |
| Ischemic heart disease | 3 (2.5) | 1 (2.5) | 2 (2.5) | NS |
| COPD | 10 (8.3) | 4 (10) | 6 (7.4) | NS |
| Active cancer | 2 (1.7) | 1 (2.5) | 1 (1.2) | NS |
| (Other) autoimmune diseases | 29 (24.0) | 20 (50) | 9 (11.1) | < 0.0001 |
Data are expressed as number and percentage or as mean ± SD (minimum–maximum range)
BMI Body Mass Index, CA cortisone acetate, DEX dexamethasone, HC hydrocortisone, PRED prednisone, COPD chronic obstructive pulmonary disease, NS not statistically significant, NA not applicable